ArticleJNCI cancer spectrum2026
Association of cancer characteristics with disability status and timing of onset among working-age cancer survivors.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNumerous studies examine the impact of cancer and disability on health-care use, financial toxicity, and health outcomes but not the relationship between cancer and disability. This study investigates whether and how cancer characteristics are associated with disability status (Social Security Disability Insurance) and timing of onset among prime working-age cancer survivors.
methodsWe used the 1999 to 2022 Surveillance, Epidemiology, and End Results file linked with Medicare data. Outcome was a categorical variable indicating no disability, disability onset ≥2 years and 0-<2 years before cancer diagnosis, and 0-<2 years and ≥2 years after diagnosis. Primary independent variables were 16 categories of cancer sites and stage at diagnosis. We employed a multivariable multinomial probit regression model, adjusting for patient and neighborhood characteristics, overall and by 5-year survival.
resultsOf the total sample (n = 97 642), 62.2%, 22.4%, and 15.4% had no, precancer, and postcancer disability, respectively. Likelihood of disability and timing of disability onset differed by cancer sites. Compared with prostate cancer survivors (lowest prevalence of disability), adjusted predicted probability of having disability ≥2 years before diagnosis was higher by 0.46 (95% CI = 0.43 to 0.49) among liver cancer survivors, whereas having disability <2 years after diagnosis was higher by 0.29 (95% CI = 0.27 to 0.32) among brain cancer survivors. Nearly all <5-year cancer survivors had disability, and the patterns of association varied significantly by 5-year survival.
conclusionsClinically assessed disability is strongly associated with specific cancer sites. These findings may point to strategies to improve efficiency of cancer prevention and care, reducing untoward impacts on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.